NORTHFIELD, Ill. (April 22, 2026) — Cell‑free DNA (cfDNA) is rapidly expanding beyond its established roles in oncology and prenatal screening, with growing relevance for transfusion medicine and laboratory practice, according to a new article by the College of American Pathologists (CAP).
The article, “The Expanding Role of Cell-Free DNA in Transfusion Medicine,” highlights how cfDNA testing is enabling more precise, less invasive approaches to prenatal care, transplant monitoring, and transfusion safety.
“Cell‑free DNA gives pathologists new insight into what’s happening inside the body using a simple blood sample,” said co-author Gagan Mathur, MD, MBA, FCAP. “As this technology continues to evolve, it has the potential to improve diagnostic accuracy, guide clinical decision‑making, and ultimately enhance patient outcomes across multiple settings.”
Advancing Safer, More Targeted Care
One of the most established applications of cfDNA in transfusion medicine is noninvasive fetal blood group genotyping, which determines fetal RhD status and other key antigens using maternal blood, eliminating the need for invasive procedures. This highly accurate approach can reduce unnecessary use of Rh immune globulin, improving safety and conserving resources. The article also highlights donor-derived cfDNA as a minimally invasive tool for monitoring transplant health, enhancing detection of rejection and helping guide treatment decisions.
Looking Ahead
Beyond current clinical applications, the article explores several emerging areas where cfDNA may further transform transfusion medicine, including:
- Measuring blood cell production to better understand conditions like anemia and low platelets without needing an immediate bone marrow biopsy
- Tracking small amounts of donor or foreign cells in patients who receive frequent transfusions
- Detecting infections by analyzing microbial DNA in the blood, helping improve safety monitoring for transfusions
“As cfDNA assay technologies advance and tissue‑specific markers become better standardized, this approach could enable more personalized monitoring and earlier detection of transfusion‑related complications,” said co-author Pearl Audon, DO, FCAP.
###
About the College of American Pathologists
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.